Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
164M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
53.7M
-
Shares change
-
+218K
-
Total reported value, excl. options
-
$143M
-
Value change
-
-$1.36M
-
Put/Call ratio
-
0.68
-
Number of buys
-
51
-
Number of sells
-
-50
-
Price
-
$2.67
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2022
127 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2022.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.7M shares
of 164M outstanding shares and own 32.7% of the company stock.
Largest 10 shareholders include BVF INC/IL (5.8M shares), RTW INVESTMENTS, LP (5.78M shares), VANGUARD GROUP INC (5.22M shares), BlackRock Inc. (4.99M shares), Point72 Asset Management, L.P. (4.37M shares), Rubric Capital Management LP (2.41M shares), MILLENNIUM MANAGEMENT LLC (2.25M shares), ORBIMED ADVISORS LLC (2.12M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), and Candriam Luxembourg S.C.A. (1.65M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.